NCT04748419: An ongoing trial by University of Nebraska
This trial is ongoing. It must report results 12 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04748419 |
|---|---|
| Title | Phase I/II Study Assessing Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Primary Lung Cancer With Durvalumab After Definitive Chemoradiation Therapy for Stage III Non-small Cell Lung Cancer |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | July 15, 2021 |
| Completion date | March 31, 2026 |
| Required reporting date | March 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |